|
gptkbp:instanceOf
|
gptkb:drug
antiemetic
|
|
gptkbp:approvalYear
|
1991
|
|
gptkbp:ATCCode
|
gptkb:A04AA01
|
|
gptkbp:brand
|
gptkb:Zofran
gptkb:Emeset
gptkb:Ondemet
|
|
gptkbp:CASNumber
|
99614-02-5
|
|
gptkbp:contraindication
|
gptkb:congenital_long_QT_syndrome
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:drugInteraction
|
apomorphine
|
|
gptkbp:eliminationHalfLife
|
3-6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C18H19N3O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ondansetron
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
5-HT3 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
293.366 g/mol
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
sublingual
|
|
gptkbp:sideEffect
|
constipation
dizziness
headache
QT prolongation
|
|
gptkbp:usedFor
|
chemotherapy-induced nausea and vomiting
postoperative nausea and vomiting
radiotherapy-induced nausea and vomiting
prevention of nausea and vomiting
|
|
gptkbp:bfsParent
|
gptkb:Zofran
|
|
gptkbp:bfsLayer
|
5
|